A drug originally developed to treat Ebola is getting a second chance in the spotlight, as research teams in the United States, Asia and Europe race to test it against the new coronavirus. This week, Northwestern University was among the latest U.S. medical centers to join a large-scale research effort sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). It is putting remdesivir to the “gold standard” test in medicine: a controlled clinical trial.